Omeros (NASDAQ: OMER)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Omeros Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Omeros Company Info
Omeros Corporation is a clinical-stage Biopharmaceutical Company engaged in discovering developing and commercializing products focused on inflammation and disorders of the central nervous system.
News & Analysis
A $200 million milestone payment sparked a rally in the biopharma's shares this week.
The Omeros will now be able to fund operations at least through 2025.
A positive regulatory development is powering the biotech's shares higher today.
It's reverting to where it was before its massive uptick last week.
Bad news the company received today from the FDA surprised investors more than it probably should have.
The narsoplimab program hasn't proceeded as swimmingly as investors thought.
The biotech stock was part of a larger Wall Street sell-off.
The biopharma announced the pricing of a public offering of common stock and debt offering.
OMER earnings call for the period ending March 31, 2020.
OMER earnings call for the period ending December 31, 2019.
OMER earnings call for the period ending September 30, 2019.
OMER earnings call for the period ending June 30, 2019.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.